View in EDS

Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma

Saved in:
Bibliographic Details
Title: Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma
Authors: Ellis, Rodney J.1,2 rje2@po.cwru.edu, Vertocnik, Amy3, Kim, Edward3, Zhou, Hang3, Young, Benjamin3, Sodee, Bruce4, Fu, Pingfu5, Beddar, Sam3, Colussi, Valdir3, Spirnak, John P.6, Dinchman, Kurt H.6, Resnick, Martin2, Kinsella, Timothy J.3
Source: International Journal of Radiation Oncology, Biology, Physics. Oct2003, Vol. 57 Issue 2, p362-370. 9p.
Subjects: Prostate cancer, Radioisotope brachytherapy, Exocrine glands, Health risk assessment
Abstract: : PurposeTo evaluate 4-year biochemical outcomes for patients with prostate adenocarcinoma who underwent radioimmunoguided (Prostascint) permanent prostate brachytherapy.: Methods and materialsEighty patients with clinical T1C–T3A NxM0 prostate cancer underwent ProstaScint-guided prostate brachytherapy using either 103Pd or 125I between February 1997 and December 2000. Sixty-seven patients underwent prostate brachytherapy alone, whereas 13 patients received neoadjuvant hormonal manipulation before implantation. Risk factors (RF) included PSA >10, Stage ≥T2b, and Gleason grade ≥7. Sixty patients had low-risk disease (0 RF), 17 were intermediate risk (1 RF), and 3 were high risk (2 RF). Biochemical disease-free survival (bDFS) was calculated using the American Society for Therapeutic Radiology and Oncology (ASTRO) consensus criteria, a PSA cutoff of 1.0 ng/mL, and a PSA cutoff of 0.5 ng/mL.: ResultsFour-year bDFS for the entire cohort was 97.4% using the ASTRO consensus criteria. Low-risk patients (60) had a 4-year bDFS of 100%; intermediate- and high-risk patients (20 patients) were 89.2%. The hormonally nai¨ve group (67 patients) had a 4-year bDFS of 96.9% and a median PSA nadir of 0.2 ng/mL. Median time to nadir was 19.8 months (range: 1.9–53.2 months). For the neoadjuvant hormonal therapy group (13 patients), ASTRO-defined bDFS was 100%. Overall, 85.2% of patients had a posttreatment PSA ≤1.0 ng/mL, and 75.9% had a PSA ≤0.5 ng/mL at a median follow-up of 36 months.: ConclusionsAt a median follow-up of 36 months, ProstaScint-guided transperineal brachytherapy results in a high probability of actuarial 4-year biochemical disease-free survival for patients with localized prostate cancer. [Copyright &y& Elsevier]
Copyright of International Journal of Radiation Oncology, Biology, Physics is the property of Pergamon Press - An Imprint of Elsevier Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
FullText Text:
  Availability: 0
Header DbId: egs
DbLabel: Engineering Source
An: 10696397
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Ellis%2C+Rodney+J%2E%22">Ellis, Rodney J.</searchLink><relatesTo>1,2</relatesTo><i> rje2@po.cwru.edu</i><br /><searchLink fieldCode="AR" term="%22Vertocnik%2C+Amy%22">Vertocnik, Amy</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Kim%2C+Edward%22">Kim, Edward</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Zhou%2C+Hang%22">Zhou, Hang</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Young%2C+Benjamin%22">Young, Benjamin</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Sodee%2C+Bruce%22">Sodee, Bruce</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Fu%2C+Pingfu%22">Fu, Pingfu</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Beddar%2C+Sam%22">Beddar, Sam</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Colussi%2C+Valdir%22">Colussi, Valdir</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Spirnak%2C+John+P%2E%22">Spirnak, John P.</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Dinchman%2C+Kurt+H%2E%22">Dinchman, Kurt H.</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Resnick%2C+Martin%22">Resnick, Martin</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Kinsella%2C+Timothy+J%2E%22">Kinsella, Timothy J.</searchLink><relatesTo>3</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22International+Journal+of+Radiation+Oncology%2C+Biology%2C+Physics%22">International Journal of Radiation Oncology, Biology, Physics</searchLink>. Oct2003, Vol. 57 Issue 2, p362-370. 9p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Prostate+cancer%22">Prostate cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Radioisotope+brachytherapy%22">Radioisotope brachytherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Exocrine+glands%22">Exocrine glands</searchLink><br /><searchLink fieldCode="DE" term="%22Health+risk+assessment%22">Health risk assessment</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: : PurposeTo evaluate 4-year biochemical outcomes for patients with prostate adenocarcinoma who underwent radioimmunoguided (Prostascint) permanent prostate brachytherapy.: Methods and materialsEighty patients with clinical T1C–T3A NxM0 prostate cancer underwent ProstaScint-guided prostate brachytherapy using either 103Pd or 125I between February 1997 and December 2000. Sixty-seven patients underwent prostate brachytherapy alone, whereas 13 patients received neoadjuvant hormonal manipulation before implantation. Risk factors (RF) included PSA >10, Stage ≥T2b, and Gleason grade ≥7. Sixty patients had low-risk disease (0 RF), 17 were intermediate risk (1 RF), and 3 were high risk (2 RF). Biochemical disease-free survival (bDFS) was calculated using the American Society for Therapeutic Radiology and Oncology (ASTRO) consensus criteria, a PSA cutoff of 1.0 ng/mL, and a PSA cutoff of 0.5 ng/mL.: ResultsFour-year bDFS for the entire cohort was 97.4% using the ASTRO consensus criteria. Low-risk patients (60) had a 4-year bDFS of 100%; intermediate- and high-risk patients (20 patients) were 89.2%. The hormonally nai¨ve group (67 patients) had a 4-year bDFS of 96.9% and a median PSA nadir of 0.2 ng/mL. Median time to nadir was 19.8 months (range: 1.9–53.2 months). For the neoadjuvant hormonal therapy group (13 patients), ASTRO-defined bDFS was 100%. Overall, 85.2% of patients had a posttreatment PSA ≤1.0 ng/mL, and 75.9% had a PSA ≤0.5 ng/mL at a median follow-up of 36 months.: ConclusionsAt a median follow-up of 36 months, ProstaScint-guided transperineal brachytherapy results in a high probability of actuarial 4-year biochemical disease-free survival for patients with localized prostate cancer. [Copyright &y& Elsevier]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of International Journal of Radiation Oncology, Biology, Physics is the property of Pergamon Press - An Imprint of Elsevier Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=10696397
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0360-3016(03)00588-1
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 9
        StartPage: 362
    Subjects:
      – SubjectFull: Prostate cancer
        Type: general
      – SubjectFull: Radioisotope brachytherapy
        Type: general
      – SubjectFull: Exocrine glands
        Type: general
      – SubjectFull: Health risk assessment
        Type: general
    Titles:
      – TitleFull: Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ellis, Rodney J.
      – PersonEntity:
          Name:
            NameFull: Vertocnik, Amy
      – PersonEntity:
          Name:
            NameFull: Kim, Edward
      – PersonEntity:
          Name:
            NameFull: Zhou, Hang
      – PersonEntity:
          Name:
            NameFull: Young, Benjamin
      – PersonEntity:
          Name:
            NameFull: Sodee, Bruce
      – PersonEntity:
          Name:
            NameFull: Fu, Pingfu
      – PersonEntity:
          Name:
            NameFull: Beddar, Sam
      – PersonEntity:
          Name:
            NameFull: Colussi, Valdir
      – PersonEntity:
          Name:
            NameFull: Spirnak, John P.
      – PersonEntity:
          Name:
            NameFull: Dinchman, Kurt H.
      – PersonEntity:
          Name:
            NameFull: Resnick, Martin
      – PersonEntity:
          Name:
            NameFull: Kinsella, Timothy J.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: Oct2003
              Type: published
              Y: 2003
          Identifiers:
            – Type: issn-print
              Value: 03603016
          Numbering:
            – Type: volume
              Value: 57
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: International Journal of Radiation Oncology, Biology, Physics
              Type: main
ResultId 1